How Often Should an AIMS Assessment Be Completed?

For most patients taking antipsychotic medications, an AIMS (Abnormal Involuntary Movement Scale) assessment should be completed at least every six to twelve months, depending on individual risk for tardive dyskinesia. That range comes from the updated 2020 American Psychiatric Association guidelines, which replaced older recommendations that called for more frequent screening on tighter schedules. The real-world picture is more complicated than a single number, though, because the right interval depends on what medication you take, how long you have been on it, and whether you carry additional risk factors.

What the Current APA Guidelines Recommend

The 2020 APA guidelines divide patients into two groups. If you are considered high-risk for tardive dyskinesia, the recommendation is an AIMS assessment every six months. If you are not in a high-risk category, screening once every twelve months is the standard.¹ This is a shift from older APA practice guidelines, which drew the line based on which type of antipsychotic a person was taking. Under the previous framework, patients on older conventional antipsychotics were supposed to be screened every three to four months, while those on newer atypical antipsychotics were screened every five to six months.¹

The change reflects a growing understanding that atypical antipsychotics, while carrying a lower risk than their older counterparts, are not free of tardive dyskinesia risk. Rather than maintaining two rigid schedules by drug class, the updated guidelines ask clinicians to look at the whole patient and determine an appropriate interval based on overall risk profile. In practice, many clinicians still aim for at least every six months for anyone on a dopamine-blocking medication, treating that as a reasonable floor.²

Who Counts as High-Risk

Several factors push someone into the higher-risk category that warrants more frequent screening. Longer duration on antipsychotic therapy is one of the most well-established. Older age is another. Women, particularly those who are postmenopausal, tend to develop tardive dyskinesia at higher rates. People with mood disorders, those who have experienced early extrapyramidal side effects from their medications, and individuals with a history of substance use disorders also carry elevated risk. If you have any combination of these factors, your provider has reason to screen you on the shorter, six-month schedule rather than waiting a full year.

Tardive dyskinesia itself affects a substantial portion of people taking long-term antipsychotic therapy. Estimates put the prevalence somewhere between 15 and 30 percent of patients on these medications over the long term.³ Those numbers make regular screening more than a bureaucratic checkbox. Catching the condition early can mean the difference between mild symptoms that respond to intervention and a movement disorder that becomes difficult to reverse.

The Importance of a Baseline Assessment

One detail that often gets overlooked is that the first AIMS assessment should happen before a patient starts antipsychotic medication, not after. The purpose of this baseline is straightforward: you need to know what someone’s involuntary movements look like at the start so that any changes can be measured against something concrete. Some patients already have subtle involuntary movements from other causes, and without a pre-treatment assessment those could later be mistaken for drug-induced tardive dyskinesia, or genuine drug-induced changes could be attributed to a pre-existing condition.¹

Despite its value, baseline testing is frequently skipped in clinical practice. When a patient is in crisis and the priority is stabilizing their psychiatric symptoms, completing a structured movement assessment before the first dose of medication can feel like a low priority. But this is an area where a few minutes up front saves a lot of confusion later. If you are starting a new antipsychotic and your provider does not mention an AIMS, it is reasonable to ask about it.

When Screening at Every Visit May Be Warranted

The formal guideline range of every three to twelve months, depending on risk, reflects a compromise between clinical thoroughness and practical constraints. Some researchers have argued that even these intervals may not be tight enough. A workshop on AIMS use in clinical settings noted that patients can develop signs of tardive dyskinesia between scheduled assessments and that those signs would be missed if clinicians rely solely on periodic screening at fixed intervals.⁴

The alternative they proposed is more conservative: rather than relying on a scheduled AIMS every few months, all patients on antipsychotics and their caregivers should be informed about self-examination for abnormal movements, and clinicians should briefly question and examine patients for involuntary movements at every clinic visit.⁴ This does not mean performing a full structured AIMS at every visit. It means incorporating a brief check for facial tics, tongue movements, or limb restlessness as part of routine appointments, and then following up with a full AIMS if anything looks different from the patient’s baseline.

This approach acknowledges a reality about tardive dyskinesia that fixed screening intervals sometimes obscure: the condition does not announce itself on a schedule. It can emerge gradually and be subtle enough that neither the patient nor their family notices until it is well established. A quick observational check at every appointment adds a layer of safety that periodic formal screening alone cannot provide.

Why Screening Falls Short in Practice

Even with clear guidelines, AIMS screening rates in real-world clinical settings are often lower than they should be. One quality improvement project at an outpatient psychiatry clinic found that a large number of patients on medications that could cause tardive dyskinesia were not being assessed with the AIMS at the recommended frequency. The project’s investigators identified several contributing factors: time pressure during appointments, lack of a built-in reminder system, and inconsistent documentation habits among providers.²

This is not unique to a single clinic. Tardive dyskinesia remains significantly under-diagnosed despite the AIMS being considered the gold standard screening tool for the condition.³ Part of the problem is structural. A standard outpatient psychiatry appointment is often 15 to 20 minutes, and there are competing priorities: reviewing medication adherence, checking on symptoms, assessing safety. The AIMS itself takes about ten minutes when performed thoroughly, which is a significant chunk of an already short visit. Clinicians sometimes rely on informal observation rather than the structured assessment, which is better than nothing but less systematic and harder to track over time.

If you are a patient or caregiver, the practical implication is that you may need to be proactive. Ask your prescriber directly whether an AIMS has been completed recently and when the next one is scheduled. If you are in a setting where your psychiatrist seems rushed, this kind of direct question can prompt the assessment to happen. You have a right to know whether you are being monitored for a known side effect of your medication.

What the AIMS Actually Measures

Understanding what happens during an AIMS assessment can make it feel less mysterious. The exam involves a series of observations and simple tasks. The clinician watches your face at rest, asks you to open your mouth and extend your tongue, observes your hands and fingers during specific movements, and watches your body and limbs for involuntary motion while you sit, stand, and walk. Each body region is scored on a scale from none to severe based on the presence and intensity of abnormal movements.

The areas covered include:

Facial muscles: furrowing of the brow, blinking, grimacing, or other involuntary facial expressions
Lips and jaw: puckering, chewing motions, lip smacking, or clenching
Tongue: protrusion, tremor, or slow writhing movements inside or outside the mouth
Upper extremities: involuntary hand, wrist, or finger movements
Lower extremities: toe tapping, foot movements, or knee bouncing
Trunk: rocking, twisting, or squirming movements of the torso

The clinician also records a global severity judgment and notes the patient’s own awareness of the movements. This last piece matters because some people with early tardive dyskinesia are completely unaware they are making involuntary movements. Others are acutely aware and distressed by them. Both the presence and the patient’s awareness factor into clinical decision-making about whether to adjust medications or start targeted treatment.

How Consistent Are AIMS Scores Between Clinicians

One concern patients sometimes have is whether the score depends on who is doing the assessment. If you see one psychiatrist this month and a different one in six months, will they rate your movements the same way? Research on this question is generally reassuring. A multi-center study that measured how well different clinicians agreed when rating the same patients using the AIMS found that overall agreement was good, with consistency scores in a range that researchers consider reliable for clinical use.⁵

The study also looked at whether clinicians’ ratings drifted over time, a phenomenon where assessors gradually shift in how strictly or loosely they apply a scale. The researchers found very little drift, with scores varying by only a tiny fraction of a point between initial and follow-up ratings of the same patients.⁵ This is good news for anyone being monitored over time, especially in settings where you might not always see the same clinician. The AIMS is structured enough that different trained raters arrive at similar conclusions.

That said, reliability in a research setting with trained raters and videotaped assessments is not always the same as reliability in a busy clinic where the assessment is done in person under time pressure. Training and standardization matter. Clinics that invest in making sure all their providers are calibrated on how to perform the AIMS tend to get more consistent results across visits, which is another reason to prefer structured assessments over informal observation.

Self-Monitoring and Caregiver Involvement

Formal AIMS assessments happen at most a few times a year, but tardive dyskinesia can emerge or worsen between appointments. This gap is where self-monitoring becomes important. Patients and their families or caregivers can learn to watch for common early signs: subtle chewing motions when the mouth is at rest, tongue movements visible through the cheeks, finger movements that were not there before, or a new tendency to shift weight or rock while seated.

Researchers who have studied the role of patient and caregiver perspectives in tardive dyskinesia screening have concluded that clinicians should consider input from both patients and caregivers when evaluating for the condition. This makes intuitive sense. A caregiver who sees you daily may notice a new facial movement long before your psychiatrist does during a quarterly visit. Patients themselves sometimes feel something is off, a sensation of restlessness or a loss of fine motor control, before visible involuntary movements become obvious to an observer.

If you are taking an antipsychotic, it helps to have a trusted person who knows to watch for these changes. Let them know what tardive dyskinesia looks like, and ask them to tell you if they notice anything new. You can also periodically watch yourself in a mirror with your mouth open and tongue extended, checking for movements you cannot feel. None of this replaces a formal AIMS, but it fills the gaps between assessments and gives your clinician useful information when you do come in for your next evaluation.

Non-Psychiatric Medications That Also Warrant Screening

Most discussions about AIMS screening focus on psychiatric patients taking antipsychotics, and that is where the largest at-risk population lives. But antipsychotic medications are not only used in psychiatry. Drugs that block dopamine receptors are also prescribed for gastrointestinal conditions, nausea, and other non-psychiatric indications. Metoclopramide, for example, is a dopamine blocker widely used for gastroparesis and nausea that carries its own risk of tardive dyskinesia, especially with long-term use.

Patients taking these medications in non-psychiatric settings may not receive the same routine screening because their prescribers are gastroenterologists or primary care physicians who are less likely to have AIMS built into their workflow. If you are on any medication that blocks dopamine and have been taking it for more than a few months, ask your doctor whether periodic screening for involuntary movements is appropriate. The same principles apply regardless of why the medication was prescribed: baseline assessment before starting, regular monitoring during treatment, and a lower threshold for screening if you carry additional risk factors.

Some facilities have begun building AIMS reminders into their electronic health record systems, flagging any patient on a dopamine-blocking medication for screening at appropriate intervals regardless of their primary diagnosis. This kind of system-level approach reduces the chance of someone slipping through the cracks simply because their medication was prescribed outside a psychiatric context.²

What Happens When an AIMS Score Is Elevated

An elevated AIMS score does not automatically mean a diagnosis of tardive dyskinesia. The score needs to be interpreted in context. A clinician will consider whether the movements are new, whether they correspond to the timing of medication changes, whether other possible causes have been ruled out, and whether the patient was already showing some involuntary movements at baseline. A score that has increased compared to a previous assessment is more clinically meaningful than an isolated score at a single time point, which is one of the strongest arguments for consistent, repeated screening.

If the assessment does point toward tardive dyskinesia, the clinical response depends on severity. For mild cases, the options might include reducing the dose of the causative medication, switching to an antipsychotic with a lower risk profile, or simply monitoring more closely to see whether the movements progress. For moderate to severe cases, there are now FDA-approved medications specifically designed to treat tardive dyskinesia, which work by a different mechanism than the antipsychotic itself. These treatments have made the condition more manageable than it was a generation ago, but early detection through regular AIMS screening remains important because outcomes tend to be better the sooner treatment begins.

The AIMS score also matters for tracking treatment response. Once someone starts a targeted therapy for tardive dyskinesia, repeat AIMS assessments at regular intervals help determine whether the treatment is working and whether the dose needs to be adjusted. In this treatment-monitoring phase, assessments may be done more frequently than the standard screening schedule, sometimes every few weeks early on, tapering to every few months once the patient is stable.

1
PubMed Central. Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative – Section: Introduction
2
PubMed Central. Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative – Section: Materials and methods
3
Digital USD. Enhancing Tardive Dyskinesia Screening in an Outpatient Psychiatry Training Clinic: A Quality Improvement Initiative
4
The Journal of Clinical Psychiatry. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop
5
International Journal of Methods in Psychiatric Research. Inter-rater reliability of the abnormal involuntary movements scale (AIMS) in a multi-centre trial: results from department of veterans affairs cooperative study #394